These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 30704164

  • 1. [Value of the detection of BRAF(V600E) gene mutation and protein expression in auxiliary cytological diagnosis of papillary thyroid carcinoma].
    Zhao H, Guo HQ, Zhang ZH, Cao J, Zhao LL, Sun Y, Wang C, Xiao T.
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan 07; 54(1):18-22. PubMed ID: 30704164
    [Abstract] [Full Text] [Related]

  • 2. The Combined Use of Fine-Needle Aspiration (FNA) and BRAF V600E Gene Testing: Can it Increase the Definitive Diagnosis Rate of Nodules Categorized as Bethesda III for Papillary Thyroid Carcinoma?
    Lei L, Hong Qing S, Wei L, Ma Mo Yang F, Xiao Xiang Y.
    Am Surg; 2024 Dec 07; 90(12):3209-3215. PubMed ID: 39047144
    [Abstract] [Full Text] [Related]

  • 3. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE, Kim LT, Hackman TG, Dodd LG.
    Cancer Cytopathol; 2015 Sep 07; 123(9):531-9. PubMed ID: 26080065
    [Abstract] [Full Text] [Related]

  • 4. Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.
    Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z.
    Tumour Biol; 2016 Jan 07; 37(1):611-8. PubMed ID: 26240026
    [Abstract] [Full Text] [Related]

  • 5. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
    Dell'Aquila M, Granitto A, Martini M, Capodimonti S, Cocomazzi A, Musarra T, Fiorentino V, Pontecorvi A, Lombardi CP, Fadda G, Pantanowitz L, Larocca LM, Rossi ED.
    Cancer Cytopathol; 2020 Mar 07; 128(3):177-189. PubMed ID: 31821747
    [Abstract] [Full Text] [Related]

  • 6. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
    Zhao H, Zhang ZH, Zhou B, Xiao T, Pan QJ, Guo HQ.
    Diagn Cytopathol; 2015 Oct 07; 43(10):786-90. PubMed ID: 26152656
    [Abstract] [Full Text] [Related]

  • 7. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK, Camenisch U, Rechsteiner MP, Bode-Lesniewska B, Rössle M.
    Cancer Cytopathol; 2014 Jan 07; 122(1):48-58. PubMed ID: 24039206
    [Abstract] [Full Text] [Related]

  • 8. BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance.
    Adeniran AJ, Hui P, Chhieng DC, Prasad ML, Schofield K, Theoharis C.
    Acta Cytol; 2011 Jan 07; 55(6):570-5. PubMed ID: 22156468
    [Abstract] [Full Text] [Related]

  • 9. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A, Guidobaldi L, Nasrollah N, Taccogna S, Cicciarella Modica DD, Turrini L, Nigri G, Romanelli F, Valabrega S, Giovanella L, Onetti Muda A, Trimboli P.
    Horm Metab Res; 2014 May 07; 46(5):370-4. PubMed ID: 24570209
    [Abstract] [Full Text] [Related]

  • 10. The Role of BRAF V600E in Reducing AUS/FLUS Diagnosis in Thyroid Fine Needle Aspiration.
    Yin L, Tang Y, Yu S, Wang C, Xiao M, Wang Y, Liu SJ, Gao L, Huang K, Jin L.
    Endocr Pathol; 2019 Dec 07; 30(4):312-317. PubMed ID: 31529211
    [Abstract] [Full Text] [Related]

  • 11. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
    Beiša A, Kvietkauskas M, Beiša V, Stoškus M, Ostanevičiūtė E, Jasiūnas E, Griškevičius L, Strupas K.
    Langenbecks Arch Surg; 2017 Mar 07; 402(2):227-234. PubMed ID: 28160058
    [Abstract] [Full Text] [Related]

  • 12. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases.
    Lee SR, Yim H, Han JH, Lee KB, Lee J, Soh EY, Kim DJ, Chung YS, Jeong SY, Sheen SS, Park SH, Kim JH.
    Am J Clin Pathol; 2015 Mar 07; 143(3):437-44. PubMed ID: 25696803
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM.
    Cancer Cytopathol; 2015 Oct 07; 123(10):593-602. PubMed ID: 26230187
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P, Brunelli C, Rossi ED, Lanza P, Martini M, Musarra T, Lombardi CP, Pontecorvi A, Fadda G.
    Cytopathology; 2019 Sep 07; 30(5):460-467. PubMed ID: 30875124
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
    Rossi ED, Bizzarro T, Martini M, Capodimonti S, Fadda G, Larocca LM, Schmitt F.
    Cancer Cytopathol; 2014 Dec 07; 122(12):883-91. PubMed ID: 25156883
    [Abstract] [Full Text] [Related]

  • 20. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAFV600E Mutation in Papillary Thyroid Carcinoma.
    Kim JK, Seong CY, Bae IE, Yi JW, Yu HW, Kim SJ, Won JK, Chai YJ, Choi JY, Lee KE.
    Ann Surg Oncol; 2018 Jun 07; 25(6):1775-1781. PubMed ID: 29611028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.